Seamus Fernandez
Stock Analyst at Guggenheim
(3.63)
# 695
Out of 4,842 analysts
99
Total ratings
48.53%
Success rate
7.08%
Average return
Main Sectors:
Stocks Rated by Seamus Fernandez
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CDTX Cidara Therapeutics | Maintains: Buy | $35 → $50 | $22.04 | +126.86% | 3 | May 16, 2025 | |
| LLY Eli Lilly and Company | Maintains: Buy | $973 → $928 | $722.57 | +28.43% | 15 | Apr 14, 2025 | |
| MBX MBX Biosciences | Reiterates: Buy | $44 | $12.76 | +244.83% | 2 | Apr 10, 2025 | |
| ARQT Arcutis Biotherapeutics | Reiterates: Buy | n/a | $13.67 | - | 3 | Apr 3, 2025 | |
| VERV Verve Therapeutics | Reiterates: Buy | n/a | $4.60 | - | 2 | Mar 25, 2025 | |
| PCVX Vaxcyte | Reiterates: Buy | $160 | $32.80 | +387.80% | 4 | Mar 12, 2025 | |
| MTSR Metsera | Initiates: Buy | $56 | $27.59 | +102.97% | 1 | Feb 25, 2025 | |
| MLYS Mineralys Therapeutics | Reiterates: Buy | n/a | $15.66 | - | 2 | Feb 24, 2025 | |
| APGE Apogee Therapeutics | Reiterates: Buy | n/a | $37.68 | - | 7 | Feb 10, 2025 | |
| MRK Merck & Co. | Maintains: Buy | $137 → $130 | $76.40 | +70.16% | 13 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $40.00 | - | 2 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $70 | $61.88 | +13.12% | 1 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $6.15 | +160.16% | 1 | Oct 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.86 | - | 3 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $5.61 | - | 3 | Apr 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | n/a | $12.74 | - | 2 | Jul 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $22.42 | +123.02% | 1 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $47.85 | - | 12 | Oct 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $69.46 | - | 2 | May 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $112.58 | - | 6 | Feb 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $8.05 | - | 1 | Feb 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $56 → $54 | $1.46 | +3,598.63% | 1 | Mar 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $60 → $45 | $19.84 | +126.81% | 3 | Mar 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $36 → $38 | $70.87 | -46.38% | 6 | Feb 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $35 → $38 | $23.45 | +62.05% | 3 | Jan 31, 2018 |
Cidara Therapeutics
May 16, 2025
Maintains: Buy
Price Target: $35 → $50
Current: $22.04
Upside: +126.86%
Eli Lilly and Company
Apr 14, 2025
Maintains: Buy
Price Target: $973 → $928
Current: $722.57
Upside: +28.43%
MBX Biosciences
Apr 10, 2025
Reiterates: Buy
Price Target: $44
Current: $12.76
Upside: +244.83%
Arcutis Biotherapeutics
Apr 3, 2025
Reiterates: Buy
Price Target: n/a
Current: $13.67
Upside: -
Verve Therapeutics
Mar 25, 2025
Reiterates: Buy
Price Target: n/a
Current: $4.60
Upside: -
Vaxcyte
Mar 12, 2025
Reiterates: Buy
Price Target: $160
Current: $32.80
Upside: +387.80%
Metsera
Feb 25, 2025
Initiates: Buy
Price Target: $56
Current: $27.59
Upside: +102.97%
Mineralys Therapeutics
Feb 24, 2025
Reiterates: Buy
Price Target: n/a
Current: $15.66
Upside: -
Apogee Therapeutics
Feb 10, 2025
Reiterates: Buy
Price Target: n/a
Current: $37.68
Upside: -
Merck & Co.
Nov 6, 2024
Maintains: Buy
Price Target: $137 → $130
Current: $76.40
Upside: +70.16%
Oct 31, 2024
Downgrades: Neutral
Price Target: n/a
Current: $40.00
Upside: -
Oct 21, 2024
Initiates: Buy
Price Target: $70
Current: $61.88
Upside: +13.12%
Oct 14, 2024
Initiates: Buy
Price Target: $16
Current: $6.15
Upside: +160.16%
Jul 8, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.86
Upside: -
Apr 29, 2024
Downgrades: Neutral
Price Target: n/a
Current: $5.61
Upside: -
Jul 14, 2023
Maintains: Buy
Price Target: n/a
Current: $12.74
Upside: -
Feb 28, 2023
Initiates: Buy
Price Target: $50
Current: $22.42
Upside: +123.02%
Oct 10, 2022
Downgrades: Neutral
Price Target: n/a
Current: $47.85
Upside: -
May 31, 2022
Upgrades: Buy
Price Target: n/a
Current: $69.46
Upside: -
Feb 25, 2020
Downgrades: Neutral
Price Target: n/a
Current: $112.58
Upside: -
Feb 3, 2020
Downgrades: Neutral
Price Target: n/a
Current: $8.05
Upside: -
Mar 13, 2018
Maintains: Outperform
Price Target: $56 → $54
Current: $1.46
Upside: +3,598.63%
Mar 8, 2018
Maintains: Market Perform
Price Target: $60 → $45
Current: $19.84
Upside: +126.81%
Feb 6, 2018
Maintains: Market Perform
Price Target: $36 → $38
Current: $70.87
Upside: -46.38%
Jan 31, 2018
Maintains: Market Perform
Price Target: $35 → $38
Current: $23.45
Upside: +62.05%